Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)

There are a number of pharmaceutical companies looking to make waves in the weight loss market.The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.The thing is that all of those treatments are manufactured by just two pharmaceutical companies, Novo Nordisk (NVO 1.54%) and Eli Lilly (LLY -0.30%). Yet despite limited competition at the moment, a number of companies of all siz ...